PET-CT for Liver Metastases: — How Reliable Is It?

A clear PET-CT is good news, but it does not guarantee there are no deposits in the liver. Small lesions and low-avidity tumours may not appear on PET at all. If your cancer type is one that commonly spreads to the liver — colorectal cancer, for example — your oncologist may still recommend a dedicated liver MRI before giving you a definitive answer. The two scans answer different questions, and your team will decide which combination is right for your situation and tumour type.

PET-CT and liver MRI are not interchangeable — they do different things. PET-CT maps disease across the whole body and is particularly strong at showing metabolically active disease in lymph nodes, lungs and bones. Liver MRI uses a different technology and detects small or low-avidity liver lesions that PET-CT does not pick up. When liver surgery or ablation is being considered, both ESMO and NCCN recommend MRI of the liver specifically. Having both scans does not mean the first was wasted — it means your team is being thorough.

Mucinous tumours produce large amounts of mucin as part of their biology. This changes how they behave metabolically — they consume less glucose than most tumours, so the FDG tracer does not concentrate in them the way it does in other cancers. On PET-CT, mucinous liver metastases may look faint or not appear at all, even when present. This is one of the best-documented limitations of PET in colorectal and appendiceal cancers, and it is why imaging decisions for these tumours need to account for tumour biology, not only the scan result.

No scan can guarantee this, and any team that says otherwise is overstating what imaging can do. MRI is significantly more sensitive than PET-CT for small liver lesions, but very small deposits — below the resolution of any current scanner — may not be visible on any imaging. This is why surgeons and oncologists make decisions based on the best available evidence rather than absolute certainty, and why imaging findings are always interpreted alongside the clinical picture and the biology of your specific cancer.

A liver MRI involves lying in the scanner while a contrast agent is given through a cannula in your arm. The contrast is taken up by healthy liver tissue over time, and images are captured at several points to show different phases of uptake. At CION, liver MRI and PET-CT are coordinated through partner imaging centres. Your care team will arrange the scan and ensure the images are reviewed by a radiologist with the appropriate specialist experience. Ask your team what preparation is needed and how long to allow on the day.

PET-CT is not replaced by MRI — it does something MRI cannot. A single PET-CT scan surveys the whole body, checking for disease in lymph nodes, lungs, bones and distant sites at the same time. For the liver, it reliably flags large and metabolically active deposits. What it cannot do is match the detail of a dedicated liver MRI for small or low-avidity lesions. In practice, both scans are used together, each contributing information the other cannot provide. The question is not which scan to use but whether both have been done.